Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Miglitol combined with metformin improves glycaemic control in type 2 diabetes
Autore:
Van Gaal, L; Maislos, M; Schernthaner, G; Rybka, J; Segal, P;
Indirizzi:
Univ Instelling Antwerp, Dept Endocrinol Metab & Clin Nutr, B-2610 Wilrijk, Belgium Univ Instelling Antwerp Wilrijk Belgium B-2610 , B-2610 Wilrijk, Belgium Ben Gurion Univ Negev, Dept Med, IL-84105 Beer Sheva, Israel Ben Gurion Univ Negev Beer Sheva Israel IL-84105 4105 Beer Sheva, Israel Hosp Rudolfstiftung, Vienna, Austria Hosp Rudolfstiftung Vienna AustriaHosp Rudolfstiftung, Vienna, Austria Bata Hosp, Zlin, Czech Republic Bata Hosp Zlin Czech RepublicBata Hosp, Zlin, Czech Republic Tel Aviv Univ, Chaim Sheba Med Ctr, IL-69978 Tel Aviv, Israel Tel Aviv Univ Tel Aviv Israel IL-69978 ed Ctr, IL-69978 Tel Aviv, Israel
Titolo Testata:
DIABETES OBESITY & METABOLISM
fascicolo: 5, volume: 3, anno: 2001,
pagine: 326 - 331
SICI:
1462-8902(200110)3:5<326:MCWMIG>2.0.ZU;2-3
Fonte:
ISI
Lingua:
ENG
Soggetto:
ALPHA-GLUCOSIDASE INHIBITOR; ACARBOSE; EFFICACY; NIDDM; GLIBENCLAMIDE; MELLITUS; DIET; REDUCTION; THERAPY; SAFETY;
Keywords:
type 2 diabetes; alpha-glucosidase inhibitor; miglitol; metformin; hyperglycaemia; postprandial;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
23
Recensione:
Indirizzi per estratti:
Indirizzo: Van Gaal, L Univ Instelling Antwerp, Dept Endocrinol, Fac Med, Wilrijkstr 10, B-2650 Antwerp, Belgium Univ Instelling Antwerp Wilrijkstr 10 Antwerp Belgium B-2650
Citazione:
L. Van Gaal et al., "Miglitol combined with metformin improves glycaemic control in type 2 diabetes", DIABET OB M, 3(5), 2001, pp. 326-331

Abstract

Aim: To investigate the efficacy and safety of miglitol vs. placebo in type 2 diabetic outpatients insufficiently controlled (HbA(1c) between 7.5 and10.5%) with diet and metformin. Methods: Patients treated with diet and metformin (1500-2250 mg/day) were randomized to receive additional treatment with either miglitol or placebo for 32 weeks. The dosages were force-titrated: 4 weeks at 25 mg miglitol t.i.d., 12 weeks at 50 mg miglitol t.i.d and 16 weeks at 100 mg miglitol t.i.d. or matching placebo. If the highest dosage could not be tolerated, patients could be down-titrated to 50 mg t.i.d. The primary efficacy criterion was the change in glycated haemoglobin (HbA(1c)). Secondary efficacy parameters included fasting and 1 h postprandial blood glucose, serum insulin. andfasting and 1 h postprandial triglyceride levels. Safety and tolerability were evaluated by the incidence of adverse events and changes in vital signs or routine biochemical and haematological parameters. Results: One hundred and fifty-two patients were valid for the intent-to-treat (ITT) analysis. There was a significant decrease in HbA1c on adding miglitol to metformin compared to adding placebo (miglitol treatment effect, -0.21%; placebo treatment effect, +0.22%; p=0.011). Postprandial blood glucose declined in both the miglitol/metformin and placebo/metformin groups with a statistically significant difference in favour of miglitol/metformin (end of treatment adjusted means 13.8 mmol/l for miglitol vs. 15.8 mmol/l for placebo, p=0.0007). Adverse events (AEs) were reported by only 8% more patients in the miglitol/metformin group than placebo/metformin. No cases of hypoglycaemia were reported. Conclusions: Miglitol can safely and effectively be added to diet and metformin inpatients whose type 2 diabetes is insufficiently controlled, and improves glycaemic control by significantly reducing HbA(1c) and postprandialblood glucose levels.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 27/01/20 alle ore 01:30:46